top of page
Accelerated Biosciences’ Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and Regenerative Medicine Treatments
May 11, 2021
Accelerated Biosciences’ ethically sourced human trophoblast stem cells (hTSCs) solve challenges for cancer-targeting therapies and regenerative medicine – offering pluripotency, immune-privilege, stability, and scalability without compromises. New data generated by Pluristyx scientists demonstrates statistically significant cytolysis with induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells programmed from its ethically sourced human trophoblast stem cells (hTSC).
bottom of page